Valneva's Lyme Disease Vaccine Falls Short in Phase III Study

Valneva's Lyme disease vaccine candidate, PF-07307405, showed a 73.2% efficacy rate but missed the primary endpoint due to fewer-than-anticipated Lyme disease cases. The vaccine demonstrated a 74.8% efficacy rate in a secondary analysis. Despite this, Valneva and Pfizer plan to move forward with regulatory submissions worldwide, positioning the vaccine as a potentially first-in-class preventive option. VALN stock nosedived 37% on the mixed results.